Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Mario Luca MorieriHe GaoMarie PigeyreHetal S ShahJennifer SjaardaChristine MendoncaTimothy HastingsPatinut BuranasupkajornAllison A Motsinger-ReifDaniel M RotroffRonald J SigalSantica M MarcovinaPeter KraftJohn B BuseMichael J WagnerHertzel C GersteinJosyf C MychaleckyjGuillaume ParèAlessandro DoriaPublished in: Diabetes care (2018)
When combined into a GRS, CAD loci identified in the general population are associated with CAD also in type 2 diabetes. This GRS provides a significant improvement in the ability to correctly predict future MCE, which may increase further with the discovery of new CAD loci.
Keyphrases
- coronary artery disease
- type diabetes
- genome wide
- risk assessment
- clinical trial
- glycemic control
- genome wide association study
- cardiovascular disease
- small molecule
- dna methylation
- genome wide association
- copy number
- current status
- heavy metals
- high throughput
- gene expression
- open label
- atrial fibrillation
- phase ii
- left ventricular
- weight loss
- single cell